A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer
- Adjuvant
- Post-surgical
- EGFR
- Exon 20
- Early Stage Lung Cancer
- Uncommon EGFR Mutations
- NSCLC, Early Stage
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Taiho Oncology, Inc.
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alaska · 1
- Alaska Oncology and Hematology · Anchorage, AK
District of Columbia · 1
- Georgetown University School of Medicine · Washington D.C., DC
Florida · 2
- D&H Cancer Research Center - Margate · Margate, FL
- Alpha Oncology Research · Orange City, FL
Illinois · 1
- University of Illinois Medical Center · Chicago, IL
Michigan · 1
- Profound Research LLC at Michigan Hematology and Oncology Consultants · Dearborn, MI
New York · 1
- Memorial Sloan Kettering Cancer Center - New York · New York, NY
Ohio · 1
- Gabrail Cancer and Research Center · Canton, OH
Virginia · 1
- Virginia Cancer Specialists - Fairfax Office · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.